Summit Therapeutics (SMMT) Grabs Investor Attention After Major FDA Breakthrough

Summit Therapeutics (NASDAQ:SMMT) is 1 of the 17 biotechnology stocks with much than 50% upside.

As of the adjacent of play connected February 12, statement sentiment astir Summit Therapeutics (NASDAQ:SMMT) was moderately bullish. The banal had received sum from 6 analysts, 4 of whom had assigned Buy ratings and 2 gave Hold calls. With nary Sell rating, the banal carries a projected median 1-year terms people of $57.98, implying a beardown upside of much than 296%.

Pressmaster/Shutterstock.com

Back connected January 29, Summit Therapeutics (NASDAQ:SMMT) confirmed that the U.S. FDA had accepted its exertion for ivonescimab, a lung crab attraction to beryllium utilized successful operation with chemotherapy successful patients who person progressed aft targeted therapy. The exertion is backed by results from the planetary signifier III HARMONi proceedings data, with November 14, 2026, being the determination date.

The exertion aims to capable a marketplace spread by catering to 14,000 eligible U.S. patients annually, on with the existing commercialized vulnerability successful China done the company’s concern with Akeso. This positions Summit Therapeutics (NASDAQ:SMMT) to perchance participate the U.S. oncology marketplace if approved.

Summit Therapeutics (NASDAQ:SMMT) is simply a clinical-stage biopharmaceutical institution that develops and commercializes aesculapian oncology therapies. It is focused connected processing ivonescimab, a bispecific antibody that combines blockade of PD-1 and anti-angiogenesis successful a azygous molecule. It is besides moving Phase III objective trials for the attraction of non-small lung cancer.

While we admit the imaginable of SMMT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.